INTRODUCTION
HCV virus, a member of the Flaviviridae family, a positive stranded RNA virus possessing an icosahedral capsid surrounded by an envelope and is mainly transmitted parentrally (1) . Chronic HCV infection is often a silent disease and may be discovered accidently during blood donation or when patients present with complications (2) . Accurate and early diagnosis of active HCV infection is of paramount importance to start treatment, prevent complications and most importantly to stop a potential source of infecting others (e.g. during blood donation or renal dialysis) (3) . The window period following acute HCV acquisition and before seroconversion takes place may range from 45 to 68 days (4) . The viral copy number of HCV RNA may reach 10 5 -10 8 copy/ml during the window period (5,6,7 ) . In addition, there is a cumulative body of data revealing that HCV-Ab titer can be negative in immunocompromised patients (e.g. on immunosuppressive medications, or undergoing hemodialysis) (8) . Currently, the diagnosis of HCV often requires the detection of anti-HCV virus antibodies and confirmation of positive results using polymerase chain reaction and recombinant immuno-blotting assay (RIBA) (9, 10) . PCR can detect HCV virus as early as 15-20 days post exposure and at a very low level of viremia (11, 12, 13) . Although PCR is highly accurate and sensitive molecular technique, it is expensive, time and labor consuming and may not be readily available in medium size or small laboratories.
Several studies have shown a potential diagnostic tool for HCV core Ag (14, 15, 16) and have indicated that the kinetics of HCV Ag are essentially identical to those of HCV RNA (17, 18) with similar early appearance in blood stream and later persistence in the circulation in parallel to HCV RNA.
HCVcore Ag detection tests have been shown to detect HCV infection 45 days (range 38-50 days) earlier than HCV-Ab screening test and 1-2 days following the detection of HCV RNA in the serum (19, 20) . Moreover, it has been reported that detection of HCV core Ag can decrease the window period interval to 23.9 days on average (21.22) . Recently Abbott launched a chemiluminescence (CMIA) kit for the detection of HCV core Ag in serum. This may represent an attractive, cost effective screening tool for high risk patients (e.g. dialysis patients, IV drug users) and may serve to quantitatively monitor virus load as a response to therapy. Similarly, HCV core Ag detection in pooled serum samples from dialysis patients may represent a quick and cheap mean of screening several patients. Several authors have suggested the periodic longitudinal screening of dialysis samples using HCV RNA or even HCV core Ag (23, 24) . The current study aimed at evaluation of the analytical performance of the Abbott architect Chemiluminescence kit in comparison to the standard PCR detection of HCV. The study also aimed to evaluate the possible clinical utility of HCV core Ag kit to detect HCV infection in pooled samples as a quick and cost saving measure to detect infection.
SUBJECTS & METHODS
The study was approved by King Fahd hospital Ethical committee. Subjects included in this study were HCV patients being followed up and treated in King Fahd hospital. Control samples were extracted from healthy subjects coming for routine checkup. Exclusion criteria included patients with mixed HCV and HBV/HIV infections and patients on steroids or chemotherapy. A written consent was taken from all subjects participating in the study. The current study included 44 HCV patients and 15 controls. For both groups, blood samples were extracted and serum was separated. The following investigations were carried out for patients and controls participating in the study; serum albumin, total protein, liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], serum alkaline phosphatase) GGT Gama glutyryl transferase, serum bilirubin, urea and creatinine, levels. These parameters were measured using RxL Dimension Clinical Chemistry analyzer (Siemens Diagnostics, Marburg GmbH, Germany). HCV core antigen was measured using Abbott Architect HCV Chemiluminescenat Microparticle Immunoassay (CMIA). The kit has a functional sensitivity of <3.0 fmol/L and a total precision of <10%. PCR reaction for HCV viral load was performed using Roche Kit (Roche Diagnostics, Indianapolis, IN, USA) according to manufacturer instructions. The kit has a lower limit of detection of 15 IU/ml and lower limit of quantitation of 43 IU/ml (25, 26) . For intra-assay precision experiment 2 samples (low and high antigenimia) were run for 20 times and the intra-assay CV was calculated. The different levels calibrators provided with the HCV core Ag kit were run 3 times and the percentage recovery was determined. The lowest HCV core Ag kit calibrator (10 fmol/L) was diluted and used to determine the assay functional sensitivity 'lower limit of quantitation; LOQ (lowest concentration with a CV<20%). Lower limit of Blank (LOB) is estimated by running 20 replicates of a known HCV negative sample. LOB was calculated as the mean+ 2 standard deviations (SD) of the 20 replicates. Both serum and EDTA plasma samples were extracted from HCV patients and controls. Serum samples were used for HCV core Ag level assay using Abbott HCV core Ag using immunoassay analyzer Architect i2000 (Abbott diagnostics, USA). EDTA samples were analyzed according to the manufacturer instructions for HCV viral load using Roche PCR quantitative kit. Samples with results above the cut-off values identified by Abbott were tested in duplicate and if any of the duplicate repeat was above the cut-off value of 3.0 fmol/L, the initial result was taken and the sample was considered positive for HCV core Ag.
Sample pooling studies: samples from known HCV patients were diluted 1:2, 1:4, 1:8 and 1: 20 using an automated sample mixer Micro lab 500 instrument (Hamilton Gastight syringe, Nevada, USA) and were tested using HCV core Ag Abbott kit.
Statistical analysis:
Normally distributed variables were expressed as Mean ± SD. The commercial statistical software package used was SPSS 11.0 (SPSS, Inc., Chicago, IL) was used for statistical evaluation of results. EP evaluator release 9 software was used for analytical evaluation studies; www.dgrhoads.com
RESULTS
Clinical and biochemical data of HCV patients and control subjects are illustrated in table1. Analytical verification of the Abbott architect HCV core Ag Kit showed a good linearity up to 600 fmol/L, while at a level of 4500 fmol/L a nonlinear curve pattern was observed (figure I). When calibrators were run in replicates of three and the mean bias and recovery were calculated, a positive bias was detected at 0 calibrator levels with a mean of 1.22 fmol/L positive bias. Similarly at higher calibrator levels, positive bias was observed, however, this was within the 20% total acceptable error (figure I). The assay showed an intra-assay CV of 7.63 % at low level antigenemia (22 fmol/L) and an intra-assay CV of 3.36 % at a high level antigenima of 7718 fmol/L. This is in agreement with the CVs quoted by Abbott that claimed a CV of 7.8 % at low level of 52.92 fmol/L and a CV of 5.6 % at high level of 7553.65 fmol/L. When the 10 fmol/L calibrator was diluted with the zero calibrator in different ratios (1:2, 1:3 and 1:4) to determine the lowest concentration detectable with a CV <20% (LOQ), a concentration of 3.3 fmol/L was shown to have a CV of 18.7%.
When HCV positive samples were diluted with serum samples from healthy HCV negative subject in different ratios, the Abbott HCV kit was able to detect HCV core Ag down to the detection limit of 3.3 fmol/L and this was dependent on the initial level of antigenemia. False negative results were obtained at low level of antigemia 3-10 fmol/L which correlated with a dilution ratio of more than 1:3.
When the results of Abbott HCV core Ag level were correlated with Roche PCR HCV copy numbers, collectively HCV core Ag testing correlated significantly with PCR molecular test (r: 0.977, p = 0.05). However, when data were stratified according to the PCR viral load results (considering PCR as the bench mark); at low level viremia (HCV copy number<= 100) there was NO significant correlation between HCV core Ag concentration results and PCR results (r: 0.281, P=0.112). Conversely at high level of viremia; PCR copy numbers=> 100 copies, there was a significant correlation between HCV core Ag concentration and PCR copy numbers (r: 0.97, P=0.01).
When cases were stratified to those positive for both HCV Core Ag and HCV RNA tests and log transformation of the data was carried out, the two tests were significantly correlated, (r:0.936, P: 0.01). The relationship between HCV RNA in IU/mL and total HCV core Ag in fmol/L was given by the following equation: HCV RNA (in log10 IU/mL) = 1.151* HCV core Ag (in log10 fmol/L) +
(figure 2)
Based on this equation, it was possible to calculate that 3 fmol/L of total HCV core Ag is equivalent to 263 IU/mL HCV RNA. Thus, total HCV core Ag is a reliable marker of HCV replication. Table II shows the result of the HCV core Ag concentration (fmol/L) and the molecular PCR testing copy numbers in 44 HCV patients and 15 controls. Out of the forty four patients tested 5 patients had false negative HCV core Ag results and 1 patient gave a positive result with undetectable HCV RNA using PCR. These results give a sensitivity of 81.0% and specificity of 97.0 % in detecting HCV virus infection using Abbott HCV core Ag kit (table  III) . 
DISCUSSION
The current study evaluated the analytical performance of Abbott Architect HCV core Ag kit in comparison with molecular HCV detection using PCR. It also evaluated the clinical utility of HCV core Ag kit in testing pooled serum samples. The current study found function sensitivity (LOQ) of 3.3. fmol/L that is more or less similar to what Abbott reports in the kit insert. Intra-assay CV were acceptable and in keeping with the manufacturer claims. However, recovery studies have shown a positive bias at different calibrator levels. When compared to the Roche PCR quantitative kit, there was a significant correlation between the two techniques at high level antigenemia. This finding is in agreement with those of Shen et al. (27) who reported a similar correlation at high level copy number (>2000). However, no significant correlation was found at low level viremia between the two techniques. This finding is of paramount importance; as at low copy number HCV RNA, patients may be missed if HCV core Ag Kit was used to diagnose early HCV infection before HCV antibodies development.
The current study revealed that 3 fmol/L core antigen is equivalent to 263 IU/mL HCV RNA which correlated with the study performed by others suggesting it is around 7000 IU/mL (12, 13) . Previous authors have indicated an overall correlation between the HCV core Ag enzyme immunoassays and Quantitative PCR and it was estimated that 1 pg/ml core antigen is equivalent with 8,000 IU/ml HCV-RNA, with small variations between patients (28) . Caruntu et al. (29) indicated that enzyme immunoassay tests for HCV core antigen do NOT detect it when HCV RNA is below 20,000 IU/ml, which limits their use in clinical practice.
In the current study, the HCV core Ag assay showed a sensitivity of 81% as it failed to correctly identify 5 cases out of 59 as true positive cases compared to the Roche PCR. This may be explained by the low sensitivity of the HCV core Ag assay at low HCV copy numbers. Another explanation of the reduced sensitivity of HCV core Ag CMIA assay is the different kinetics of RNA virus replication and the core Ag production. HCV half-life has been determined to be around 2.7 hours suggesting that HCV infection is highly dynamic (30) with variable HCV core Ag production. This varying rate of replication and hence HCV core Ag production may represent another explanation of the incomplete agreement between the HCV core Ag CMIA assay and the molecular PCR detection of the virion. It is unlikely that the presence of the HCV antibody blocking the core antigen could attribute to the reduced sensitivity of the assay. The Architect HCV core Ag assay detects HCV core Ag despite the presence of HCV antibodies due to the pretreatment step which causes lysis of viral particles and dissociation of Ag-Ab complex.
On the other hand, at high level of viremia, HCV core Ag is present at concentrations above the sensitivity of the assay and no false negatives would be present allowing the accurate identification of HCV positive patients.
The false negative results that we reported at the current study may not only be explained by the poor sensitivity of the assay under certain copy numbers, but also due to low level of antigen production or the lag phase of HCV core Ag production after HCV replication A previous study has indicated that after exposure to HCV infection, HCV core Ag can be detected 1-2 days later than HCV RNA (27) . In the current study when HCV positive samples were diluted with normal patients sera at different proportions (to mimic sample pooling), a linear dilution pattern was obtained that detected HCV core Ag down to the limit of sensitivity of the assay. Thus, this approach may be useful if there is high HCV core antigen concentration in serum to start with which may not always be the case. Samples with low concentration antigenemia (i.e. between 3-10 fmol/L) were not correctly identified as positive HCV when diluted by pooling (e.g. 1:2 or: 1:3 dilutions). Furthermore, another limiting factor of this pooling strategy is the possible reduced HCV core Ag sensitivity at certain low HCV copy numbers as illustrated in this study. In a recent meta-analysis (31) it was concluded that the current HCV core antigen assays may not displace HCV RNA assays to be a definitive diagnosis of HCV infection due to the reduced assay sensitivity (84%). Although the current study was carried out on a relatively low number of Saudi patients, it has clearly shown a limited sensitivity of HCV core Ag assay for detection of HCV positivity at low level of viremia. This observation is of paramount importance in alerting the attention for the limitation of this assay and possible drawbacks of using it as sole indictor for HCV status. Another important finding of the current study is illustrating the health risk associated with using HCV core Ag as a sole test for screening HCV infection. However, this study was carried out on a group of chronic HCV patients receiving treatment and the extrapolation of the inadequacy of HCV core Ag for screening of other special patients groups may not be entirely solid. Thus, conducting a study on a bigger scale and on different cohorts of patients with low level viremia (e.g. recently HCV infected dialysis patients) may be warranted.
In summary the current study demonstrated a sensitivity of 81.0% and specificity of 97% for the ABBOTT HCV core Ag kit assay in detecting HCV positive cases compared to quanititative PCR assay. Such levels of sensitivity and specificity may differ in different groups of HCV infected patients. The most important finding of the current study is that HCV core Ag assays may have false negative results at low level viremia (low HCV copy numbers) and does not support using HCV core Ag as a single test for screening possible HCV cases. Future directions may involve correlation of the HCV core Ag assay with different HCV genotypes and determination of correlation of HCV core Ag and PCR at different copy numbers so that the kinetic of the HCV core Ag production in relation to HCV virus replication can be estimated.
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